Compare iShares MSCI Australia ETF (EWA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Incyte Corporation — how do they compare? iShares MSCI Australia ETF trades at $29.78, while Incyte Corporation trades at $120.49 (market cap $24.48B). Which is the better fit depends on your goals.
| EWA | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $129.93 |
52-Week Low | $24.95 | $81.66 |
Market Cap | — | $24.48B |
Enterprise Value | — | $19.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $29.89, down 0.53% on the day, with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings, with RSI near 69 indicating mild overbought conditions. A dividend of $0.40 is scheduled for June 2026, providing income appeal. Recent news highlights partnerships and economic developments affecting Australian markets, though specific financial ratios are unavailable.
Outlook is cautiously optimistic due to technical strength, but limited fundamental data poses valuation challenges. Risks include reliance on Australian economic conditions and market volatility. Investors should seek updated financials for a complete assessment, as current metrics are not provided, emphasizing the need for due diligence amid geopolitical and regulatory factors.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
